These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29757039)

  • 1. Opportunities and challenges in the design of selective TAAR1 agonists: an editorial.
    Cichero E
    Expert Opin Ther Pat; 2018 Jun; 28(6):437-440. PubMed ID: 29757039
    [No Abstract]   [Full Text] [Related]  

  • 2. Design, Synthesis, and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists.
    Chiellini G; Nesi G; Digiacomo M; Malvasi R; Espinoza S; Sabatini M; Frascarelli S; Laurino A; Cichero E; Macchia M; Gainetdinov RR; Fossa P; Raimondi L; Zucchi R; Rapposelli S
    J Med Chem; 2015 Jun; 58(12):5096-107. PubMed ID: 26010728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting species-specific trace amine-associated receptor 1 ligands: to date perspective of the rational drug design process.
    Cichero E; Tonelli M
    Future Med Chem; 2017 Sep; 9(13):1507-1527. PubMed ID: 28791911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present).
    Tonelli M; Cichero E
    Expert Opin Ther Pat; 2020 Feb; 30(2):137-145. PubMed ID: 31865810
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
    Tonelli M; Espinoza S; Gainetdinov RR; Cichero E
    Eur J Med Chem; 2017 Feb; 127():781-792. PubMed ID: 27823885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hit-to-Lead Optimization of Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists with a Diphenylmethane-Scaffold: Design, Synthesis, and Biological Study.
    Chiellini G; Nesi G; Sestito S; Chiarugi S; Runfola M; Espinoza S; Sabatini M; Bellusci L; Laurino A; Cichero E; Gainetdinov RR; Fossa P; Raimondi L; Zucchi R; Rapposelli S
    J Med Chem; 2016 Nov; 59(21):9825-9836. PubMed ID: 27731647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structures of G protein-coupled receptors reveal new opportunities for drug discovery.
    Cooke RM; Brown AJ; Marshall FH; Mason JS
    Drug Discov Today; 2015 Nov; 20(11):1355-64. PubMed ID: 26303408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of Ca
    Ma Q; Ye L; Liu H; Shi Y; Zhou N
    Expert Opin Drug Discov; 2017 May; 12(5):511-523. PubMed ID: 28277837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing for inverse agonism with constitutive receptor systems.
    Kenakin T
    Curr Protoc Pharmacol; 2006 Apr; Chapter 9():Unit9.5. PubMed ID: 22294179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based drug design for G protein-coupled receptors.
    Congreve M; Dias JM; Marshall FH
    Prog Med Chem; 2014; 53():1-63. PubMed ID: 24418607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?
    Hothersall JD; Brown AJ; Dale I; Rawlins P
    Drug Discov Today; 2016 Jan; 21(1):90-96. PubMed ID: 26226643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
    Revel FG; Moreau JL; Pouzet B; Mory R; Bradaia A; Buchy D; Metzler V; Chaboz S; Groebke Zbinden K; Galley G; Norcross RD; Tuerck D; Bruns A; Morairty SR; Kilduff TS; Wallace TL; Risterucci C; Wettstein JG; Hoener MC
    Mol Psychiatry; 2013 May; 18(5):543-56. PubMed ID: 22641180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrphostin analogs are GPR35 agonists.
    Deng H; Hu H; Fang Y
    FEBS Lett; 2011 Jun; 585(12):1957-62. PubMed ID: 21601572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012.
    Galley G; Stalder H; Goergler A; Hoener MC; Norcross RD
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5244-8. PubMed ID: 22795332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structures of class B G protein-coupled receptors: prospects for drug discovery.
    Hausch F
    Angew Chem Int Ed Engl; 2013 Dec; 52(49):12783-5. PubMed ID: 24127232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cAMP assays in GPCR drug discovery.
    Vasudevan NT
    Methods Cell Biol; 2017; 142():51-57. PubMed ID: 28964339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPCR assay automation for leveraging lead optimization.
    Cvijic ME; Chen J; Kubala S; Nolfo J; Kolodin G; Zhang L
    J Lab Autom; 2012 Aug; 17(4):266-74. PubMed ID: 22505604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.
    Revel FG; Moreau JL; Gainetdinov RR; Ferragud A; Velázquez-Sánchez C; Sotnikova TD; Morairty SR; Harmeier A; Groebke Zbinden K; Norcross RD; Bradaia A; Kilduff TS; Biemans B; Pouzet B; Caron MG; Canales JJ; Wallace TL; Wettstein JG; Hoener MC
    Biol Psychiatry; 2012 Dec; 72(11):934-42. PubMed ID: 22705041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and Future Challenges in GPCR Drug Discovery.
    Topiol S
    Methods Mol Biol; 2018; 1705():1-21. PubMed ID: 29188556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPCR profiling: from hits to leads and from genotype to phenotype.
    Cvijic ME; Sum CS; Alt A; Zhang L
    Drug Discov Today Technol; 2015 Nov; 18():30-7. PubMed ID: 26723890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.